Please try another search
Pharnext SA, a clinical-stage biopharmaceutical company, engages in the development of therapies for neurodegenerative diseases with high unmet medical needs. Its products include PXT3003, a novel fixed-dose synergistic combination of baclofen, naltrexone, and sorbitol formulated that is in Phase III clinical trials for the treatment of Charcot-Marie-tooth disease type 1A; and PXT864 to treat amyotrophic lateral sclerosis. The company was incorporated in 2007 and is headquartered in Paris, France.
Name | Age | Since | Title |
---|---|---|---|
Daniel E. Cohen | 70 | - | Director |
Ilya Chumakov | - | - | Co-Founder, Chairman of Scientific Advisory Board and Director |
Jean Combalbert | - | 2020 | Director |
Lawrence Steinman | - | 2020 | Director |
Joshua Schafer | - | 2020 | Director |
Hugo Brugiere | - | 2022 | CEO & Chairman |
Guy-Charles Fanneau de la Horie | 65 | 2023 | Member of the Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review